• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward Revenues Up 23%

Phase Forward Revenues Up 23%

October 29, 2008
CenterWatch Staff

Waltham, Mass.-based eClinical technology company Phase Forward reported a 23% jump in third quarter revenues to $43 million from $34.9 million in the third quarter of 2007.

Non-GAAP net income for the period slid to $5.4 million compared with $6.9 million in the third quarter of 2007. The decline was due primarily to an increase in the company’s tax rate from 10.3% in the third quarter of 2007 to 36.2%, according to Phase Forward president and CEO Bob Weiler.

Weiler mentioned a number of Q3 highlights for the company, including a multi-year extension agreement with Eli Lilly and the recent acquisition of Clarix, a privately held provider of Web-integrated interactive response technology (IRT) based in Radnor, Pa.

“We continue to be optimistic about Phase Forward’s long-term opportunity, particularly considering the fact that we have recently expanded our market opportunity and value proposition with the acquisition of Clarix and its next generation interactive response technologies,” Weiler said in a company release. “The company’s broad range of offerings combined with our strong, debt-free balance sheet makes Phase Forward a financially secure business partner.”

Phase Forward's shares closed down 1.8% at $13.08 on Tuesday.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing